Clinical Trial

Cabotegravir-Hormone PK/PD Interactions for HIV Prevention

Study acronym: CHIPP-PrEP
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical problems when taking CAB-LA.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-06-22; most recent amendment 2026-07-10.
Trial Details
NCT Number NCT07672717
Lead Sponsor Johns Hopkins University
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions HIV, Prophylaxis, Injectable
Enrollment 32 participants
Start Date 2026-07-07
Primary Completion 2030-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-13